Evidence map›Paper›PMID 40137305›Full record

ArticleMarine drugs2025

A High-Throughput Biosensing Approach for Rapid Screening of Compounds Targeting the hNav1.1 Channel: Marine Toxins as a Case Study.

Huijing Shen, Yuxia Cui, Shiyuan Liang, Shuang Zhou, Yingji Li, Yongning Wu, Junxian Song

Abstract read
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huijing ShenSchool of Food and Health, Beijing Technology and Business University, Beijing 100048, China.
Yuxia CuiDepartment of Cardiology, Center for Cardiovascular Translational Research, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People's Hospital, Beijing 100044, China.ORCID 0000-0002-0425-4206
Shiyuan LiangNHC Key Laboratory of Food Safety Risk Assessment, Food Safety Research Unit (2019RU014) of Chinese Academy of Medical Science, China National Center for Food Safety Risk Assessment, Beijing 100021, China.
Shuang ZhouNHC Key Laboratory of Food Safety Risk Assessment, Food Safety Research Unit (2019RU014) of Chinese Academy of Medical Science, China National Center for Food Safety Risk Assessment, Beijing 100021, China.
Yingji LiICE Bioscience Inc., Beijing 100176, China.
Yongning WuSchool of Food and Health, Beijing Technology and Business University, Beijing 100048, China.ORCID 0000-0001-6430-1302
Junxian SongDepartment of Cardiology, Center for Cardiovascular Translational Research, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People's Hospital, Beijing 100044, China.

Funding

Beijing Natural Science Foundation 7252150Chinese Academy of Medical Science Research Unit Program 2019-12M-5-024National Key Research and Development Program of China 2022YFF1100802National Natural Science Foundation of China 32472456National Natural Science Foundation of China 82070519
6 · The paper itself

Abstract

Voltage-gated sodium (Nav) channels play a crucial role in initiating and propagating action potentials throughout the heart, muscles and nervous systems, making them targets for a number of drugs and toxins. While patch-clamp electrophysiology is considered the gold standard for measuring ion channel activity, its labor-intensive and time-consuming nature highlights the need for fast screening strategies to facilitate a preliminary selection of potential drugs or hazards. In this study, a high-throughput and cost-effective biosensing method was developed to rapidly identify specific agonists and inhibitors targeting the human Nav1.1 (hNav1.1) channel. It combines a red fluorescent dye sensitive to transmembrane potentials with CHO cells stably expressing the hNav1.1 α-subunit (hNav1.1-CHO). In the initial screening mode, the tested compounds were mixed with pre-equilibrated hNav1.1-CHO cells and dye to detect potential agonist effects via fluorescence enhancement. In cases where no fluorescence enhancement was observed, the addition of a known agonist veratridine allowed the indication of inhibitor candidates by fluorescence reduction, relative to the veratridine control without test compounds. Potential agonists or inhibitors identified in the initial screening were further evaluated by measuring concentration-response curves to determine EC

Indexed as

Biosensing TechniquesHigh-Throughput Screening AssaysMarine ToxinsNAV1.1 Voltage-Gated Sodium ChannelAnimalsCHO CellsCricetinaeCricetulusFluorescent DyesHumansVeratridineFluorescent DyesMarine ToxinsNAV1.1 Voltage-Gated Sodium ChannelVeratridinefluorescence sensing detectionhigh-throughput screeninghNav1.1marine toxinsvoltage-gated sodium channels

Identifiers

PMID40137305
PMCPMC11943507

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.